Bionomics Limited

102 articles with Bionomics Limited

• Bionomics Limited Release: Latest BNC210 Anxiety Drug Data to Be Presented at US Neuroscience Conference

  11/15/2010

• Bionomics Limited Announces $15 Million Capital Raising

  9/8/2009

• Bionomics Limited Start-Up Placement with Australian Ventures

  9/3/2009

• Bionomics Limited Extends Contract of CEO and Managing Director Deborah Rathjen

  8/8/2008

• Bionomics Limited Completes GMP Synthesis of Anti-Anxiety Drug BNC210

  7/9/2008

• Merck Serono and Bionomics Limited Announce Multiple Sclerosis Development and Licensing Agreement

  6/18/2008

• Bionomics Limited Advances BNC210, Anti-anxiety Lead Candidate

  3/11/2008

• Treatment of First Patient in Phase I Clinical Trial of Bionomics Limited's Anti-Cancer Drug BNC105

  2/26/2008

• Bionomics Limited Achieves US$1 Million Milestone Payment from Genmab A/S

  2/19/2008

• Bionomics Limited Anti-Cancer Compound Targets Tumour, Not Healthy Tissue

  10/4/2007

• Bionomics Limited' 2006/2007 Preliminary Final Results

  8/30/2007

• Backing for Bionomics Limited to Test Anti-Cancer Compound

  8/6/2007

• Bionomics Limited Presents Multiple Sclerosis and Anxiety Data

  7/13/2007

• Bionomics Limited Raises $10 Million in Private Placement

  6/20/2007

• Bionomics Limited' Validates Third Cancer Application For Anti-Cancer Compound BNC105

  6/4/2007

• Bionomics Limited Completes GMP Synthesis Of Cancer Drug Bnc105 On Time And On Budget

  4/23/2007

• Bionomics Limited Takes Key Step Forward in the Development of Anti-Cancer Drug Bnc105

  2/21/2007

• Bionomics Limited And SAFC Pharma Sign Contract To Manufacture BNC105

  10/25/2006

• Genmab A/S Licenses Angiogenesis Targets From Bionomics Limited

  2/14/2006

• Bionomics Limited Licenses Two Epilepsy Diagnostics To Laboratory Corporation of America Holdings

  11/3/2005